Usona completes FDA submission of psilocybin NDA for major depressive disorder
Usona Institute has completed its submission of a new drug application to the US Food and Drug Administration for its psilocybin candidate for major depressive disorder.
Usona Institute has completed its submission of a new drug application to the US Food and Drug Administration for its psilocybin candidate for major depressive disorder.
The Institute for Clinical and Economic Review announced on Wednesday it will evaluate the clinical effectiveness and cost of Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression, with results to be discussed at the May 2027 meeting of the New England Comparative Effectiveness Public Advisory Council.
Medical providers, veterans, legal experts and the legislative sponsor of New Mexico's Medical Psilocybin Act criticised draft rules 7.35.3 and 7.35.2 NMAC at an Oct. 2 public hearing before the New Mexico Department of Health, arguing the proposed prescriber gateway, landlord consent requirements and staffing ratios exceed the statute and could block access. The department is accelerating the program's launch to December 2026, a year ahead of the statutory deadline. Speakers said the rules would require an in-person exam with a certifying clinician, patient identification cards and up to 30 days of state review, and that landlord sign-off for homebound patients and leased healing centres conflicts with fair housing law; some clinical educators praised the draft training and supervision standards. Sixteen advocacy and clinical organisations have asked Rep. Nathan P. Small to add $500,000 for the Treatment Equity Fund and $500,000 for University of New Mexico palliative research.
The U.S. Department of Veterans Affairs launched PIVOT on August 5, a five-site trial of Compass Pathways' COMP360 psilocybin in veterans with treatment-resistant depression.